These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 38694413)

  • 1. Safety and Efficacy of Dotinurad on Uric Acid in Patients With Chronic Kidney Disease With Estimated Glomerular Filtration Rate Below 25 mL/Min/1.73 m².
    Mima A; Gotoda H; Lee S
    Cureus; 2024 Mar; 16(3):e57362. PubMed ID: 38694413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Efficacy and Safety of Dotinurad on Uric Acid and Renal Function in Patients with Hyperuricemia and Advanced Chronic Kidney Disease: A Single Center, Retrospective Analysis.
    Yanai K; Hirai K; Kaneko S; Mutsuyoshi Y; Kitano T; Miyazawa H; Ito K; Ueda Y; Ookawara S; Morishita Y
    Drug Des Devel Ther; 2023; 17():3233-3248. PubMed ID: 37941891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of dotinurad in patients with severe renal dysfunction.
    Kurihara O; Yamada T; Kato K; Miyauchi Y
    Clin Exp Nephrol; 2024 Mar; 28(3):208-216. PubMed ID: 37864678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urate Transporter 1 Can Be a Therapeutic Target Molecule for Chronic Kidney Disease and Diabetic Kidney Disease: A Retrospective Longitudinal Study.
    Yanai H; Katsuyama H; Hakoshima M; Adachi H
    Biomedicines; 2023 Feb; 11(2):. PubMed ID: 36831103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of mild and moderate renal dysfunction on pharmacokinetics, pharmacodynamics, and safety of dotinurad: a novel selective urate reabsorption inhibitor.
    Fukase H; Okui D; Sasaki T; Fushimi M; Ohashi T; Hosoya T
    Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):17-24. PubMed ID: 31823130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative study of a novel selective urate reabsorption inhibitor "dotinurad" among patient groups with different stages of renal dysfunction.
    Takahashi T; Beppu T; Hidaka Y; Hosoya T
    Clin Exp Nephrol; 2021 Dec; 25(12):1336-1345. PubMed ID: 34328574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia.
    Kuriyama S
    Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):1-5. PubMed ID: 31754883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dotinurad restores exacerbated kidney dysfunction in hyperuricemic patients with chronic kidney disease.
    Amano H; Kobayashi S; Terawaki H
    BMC Nephrol; 2024 Mar; 25(1):97. PubMed ID: 38491453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Possible Therapeutic Application of the Selective Inhibitor of Urate Transporter 1, Dotinurad, for Metabolic Syndrome, Chronic Kidney Disease, and Cardiovascular Disease.
    Yanai H; Adachi H; Hakoshima M; Iida S; Katsuyama H
    Cells; 2024 Mar; 13(5):. PubMed ID: 38474414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The proteinuria-lowering effects of dapagliflozin are associated with an initial decline in estimated glomerular filtration rate in patients with chronic kidney disease.
    Murakoshi M; Kobayashi T; Kihara M; Ueda S; Suzuki Y; Gohda T
    Nephrology (Carlton); 2023 Oct; 28(10):540-547. PubMed ID: 37357381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: randomized, multicenter, double-blind, placebo-controlled, parallel-group, confirmatory phase 2 study.
    Hosoya T; Sano T; Sasaki T; Fushimi M; Ohashi T
    Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):53-61. PubMed ID: 31792640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: an exploratory, randomized, multicenter, double-blind, placebo-controlled, parallel-group early phase 2 study.
    Hosoya T; Sano T; Sasaki T; Fushimi M; Ohashi T
    Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):44-52. PubMed ID: 31754882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uric acid-lowering effect of dotinurad, a novel selective urate reabsorption inhibitor, in hypertensive patients with gout or asymptomatic hyperuricemia: a pooled analysis of individual participant data in phase II and III trials.
    Takahashi T; Beppu T; Hidaka Y; Hosoya T
    Clin Exp Hypertens; 2021 Nov; 43(8):730-741. PubMed ID: 34425059
    [No Abstract]   [Full Text] [Related]  

  • 14. Potentiation of the Uricosuric Effect of Dotinurad by
    Fujita K; Zhu Q; Arakawa H; Shirasaka Y; Tamai I
    Drug Metab Dispos; 2023 Nov; 51(11):1527-1535. PubMed ID: 37643882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of switching from febuxostat to dotinurad, a novel selective urate reabsorption inhibitor, in hyperuricemic patients with type 2 diabetic kidney disease: Protocol for a single-arm, open-label, prospective, exploratory study.
    Osonoi T; Saito M; Hosoya M; Douguchi S; Ofuchi K; Katoh M
    Front Endocrinol (Lausanne); 2022; 13():1042061. PubMed ID: 36714585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of different urinary uric acid indicators in patients with chronic kidney disease.
    Guan H; Zheng Y; Zhou X; Xu Y; Fu C; Xiao J; Ye Z
    BMC Nephrol; 2020 Jul; 21(1):290. PubMed ID: 32698778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uric acid and incident chronic kidney disease in dyslipidemic individuals.
    Barkas F; Elisaf M; Liberopoulos E; Kalaitzidis R; Liamis G
    Curr Med Res Opin; 2018 Jul; 34(7):1193-1199. PubMed ID: 28836857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect for hyperuricemia inpatient of uric acid overproduction type or in combination with topiroxostat on the pharmacokinetics, pharmacodynamics and safety of dotinurad, a selective urate reabsorption inhibitor.
    Okui D; Sasaki T; Fushimi M; Ohashi T
    Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):92-102. PubMed ID: 31734820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A non-inferiority study of the novel selective urate reabsorption inhibitor dotinurad versus febuxostat in hyperuricemic patients with or without gout.
    Hosoya T; Furuno K; Kanda S
    Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):71-79. PubMed ID: 31970593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Dapagliflozin on Serum Uric Acid Levels in Patients with Advanced Chronic Kidney Disease.
    Mori D; Kobayashi M; Wada M; Tokuchi M; Misegawa S; Saito R; Nomi H; Haga R; Nagatoya K; Yamauchi A
    Intern Med; 2024 Feb; 63(3):353-357. PubMed ID: 37344435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.